Redox Signaling and Oxidative Stress Group, Danish Cancer Society Research Center, 2100 Copenhagen, Denmark.
Cell Stress and Survival Unit, Danish Cancer Society Research Center, 2100 Copenhagen, Denmark.
Biochem Pharmacol. 2020 Jun;176:113885. doi: 10.1016/j.bcp.2020.113885. Epub 2020 Feb 27.
The downregulation of the denitrosylating enzyme S-nitrosoglutathione reductase (GSNOR, EC:1.1.1.284), is a feature of hepatocellular carcinoma (HCC). This condition causes mitochondrial rearrangements that sensitize these tumors to mitochondrial toxins, in particular to the mitochondrial complex II inhibitor alpha-tocopheryl succinate (αTOS). It has also been reported the GSNOR depletion impairs the selective degradation of mitochondria through mitophagy; however, if this contributes to GSNOR-deficient HCC cell sensitivity to αTOS and can be applied to anticancer therapies, is still not known. Here, we provide evidence that GSNOR-deficient HCC cells show defective mitophagy which contributes to αTOS toxicity. Mitophagy inhibition by Parkin (EC: 2.3.2.31) depletion enhances αTOS anticancer effects, thus suggesting that this drug could be effective in treating mitophagy-defective tumors.
一氧化氮合酶还原酶(GSNOR,EC:1.1.1.284)的下调是肝细胞癌(HCC)的一个特征。这种情况会导致线粒体重排,使这些肿瘤对线粒体毒素敏感,特别是对线粒体复合物 II 抑制剂α生育酚琥珀酸酯(αTOS)敏感。也有报道称,GSNOR 耗竭会损害通过线粒体自噬选择性降解线粒体;然而,这是否有助于 GSNOR 缺陷型 HCC 细胞对 αTOS 的敏感性,以及是否可应用于癌症治疗,目前尚不清楚。在这里,我们提供的证据表明,GSNOR 缺陷型 HCC 细胞表现出有缺陷的线粒体自噬,这有助于 αTOS 的毒性。Parkin(EC:2.3.2.31)耗竭抑制线粒体自噬增强了 αTOS 的抗癌作用,因此表明该药物可能对治疗线粒体自噬缺陷型肿瘤有效。